Cambridge Investment Research Advisors, Inc. Biogen Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $27.1 Billion
- Q2 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 3,379 shares of BIIB stock, worth $661,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,379
Previous 3,769
10.35%
Holding current value
$661,033
Previous $813,000
3.69%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding BIIB
# of Institutions
1,050Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.25 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$3.2 Billion2.78% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.84 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.39 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$1.11 Billion0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $28.2B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...